TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change From Baseline at Week 6 on the Modified Ashworth Scale (MAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Physician Global Impression of Change (PGIC) Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Boston Carpal Tunnel Syndrome Symptom Severity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: functional MRI activation affected vs healthy side
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Characterization of inherited urologic malignant disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Genetic etiology of hereditary urologic malignant disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation of mutations with disease phenotypic expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of assumed trigger or risk factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transferred tissue dimensions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to established circulatory stability for > 2 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to reaching a state of no or mild pain problem for > 2 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the times eggs were consumed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in the consumption of two or more eggs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in the availability of eggs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: In vivo redox status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Loco-regional control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Rest-stress Millar pressure-volume measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean change in questionnaire's scoring
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cardiovascular health markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Duration of invasive disease free survival
Endpoint domain: Mortality/survival
Primary endpoint: Compliance of residual limb in the socket
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fit and comfort of the prosthesis
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: AUC of serum glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Immunogenicity (seroconversion and seroprotection rates)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: longitudinal structural changes in the brain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: 50% TOF-recovery after sugammadex
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urine carcinogen biomarker of exposure (NNAL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Nijmegen questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in neural connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants With Disease Progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Reduction in Menstruation to Normal Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline Score of the Sheehan Disability Scale Through 6 Weeks
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change of Mean Score of the Behavioral Health Measure-20 Between Baseline and End of Study
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Subjective usability ratings
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Survival without neurological symptoms
Endpoint domain: Mortality/survival
Primary endpoint: Maximal Inspiratory and Expiratory Pressures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Retrieved lymph nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Rate of success of radiofrequency treatment for stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Complete Breast Imaging Datasets
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Pain Intensity and Unpleasantness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Achalasia severity questionnaire score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With HIV-1 RNA Levels Less Than 400 Copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: recovery of BV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline of HbA1C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hours Slept
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change from Baseline in Body Weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of patients completed detoxification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of samples with concordant results for marker detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Optimal reader cut-offs for serum and blood samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of more targeted treatments prescribed
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Plasma homocysteine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma glutathione (GSH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Outcome expectancy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Scoring Changes in the Pictorial Blood Loss Assessment Chart (PBAC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Absolute Change From Baseline in FEV1 Percent Predicted
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Changes in HIV testing Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Knowledge of HIV status
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in Linkage to confirmatory HIV testing
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mean Change From Baseline in Nasolabial Fold Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Nasolabial Folds With ≥1-Point Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preference for SC or IV Route of Administration
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: adequate support of perineum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cycling distance in meters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of negative symptoms of psychosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: endoscopic access
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Correlation of plasma levels and pharmacokinetics with disease burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation of tumor markers with disease burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Utility of tumor markers for following patients after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Cardiopulmonary function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of patients with ACR70 response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neer classification system score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Experienced Clinical Worsening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose delivered to the patient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SOD1 half-life in CSF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved Symptoms Based on Reflux Symptom Index (RSI) Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improved Symptoms Based on Reflux Severity Index (RSI) Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improved Symptoms Based on GERD Health Related Quality of Life (GERD-HRQL) Questionnaire Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Wrinkle Severity Rating Scale (WSRS) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Had Access to, and Received the Intervention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Score of muscular strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Incidence of product-related treatment-emergent adverse events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Bristol Stool Scale (BSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Responder Status at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anxiety scores from STAI questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Total intraoperative opioid consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Total intraoperative propofol consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Chilblains' topography evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in QNPZ-5 scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time to development of symptomatic peripheral neuropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in peripheral neuropathy symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Total Limb Fat Mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in zinc-regulated cellular proteins
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1 year recurrent free survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Dose Limiting Toxicity Incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Stroop Color test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Stroop Word test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Trail Making task A
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Response rates (complete or partial response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with absence of inflammation in liver biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Change in Dilution-to-Threshold (D/T) values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Systemic adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Healthcare Resource Utilization
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Continuous tissue oximetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Drug Concentration (Cmax) for Telotristat Ethyl
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Maximum Observed Plasma Concentration (Tmax) for Telotristat Ethyl
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration Time Curve From 0 to Time t Corresponding to the Last Quantifiable Concentration (AUC[0-tlast]) for Telotristat Ethyl
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed plasma concentration of GLPG1972
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentration of GLPG1972 24hrs post-dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to achieve maximal plasma concentration of GLPG1972
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Last quantifiable plasma concentration of GLPG1972
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative incidence of grade ≥ 3 acute dermatitis
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of cesarean scar defects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Maternal Serum Magnesium Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of postoperative residual neuromuscular blockade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Medical Outcomes Study Scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: AVT overall mean challenge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of CD4 and CD8 T cells expressing cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Sympatho-vagal instability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Correlation between VASr and ultrasonography findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Days between two failures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of psoriatic severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Improvement of endothelial function (assessed by FMD changes)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Sport Related Concussion injuries
Endpoint domain: Adverse events/effects
Primary endpoint: Progression free rate (PFR) at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: level of contrast medium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of CVAD Line Thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Clinical Disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Clinical to Pathologic Downstaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Changes in scores during early rehabilitation
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in width of alveolar ridge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in IKDC score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hoogland Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrent Stage II or Greater Anterior Vaginal Prolapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Incidence of candidemia
Endpoint domain: Mortality/survival
Primary endpoint: Height velocity standard deviation score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in risk behaviors
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change From Baseline in Trans-epidermal Water Loss (TEWL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Cmax - Maximum Observed Plasma Concentration of 9-1067
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prognosis in patients who have recovered from COVID-19
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endsystolic elastance (Ees)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of elimination of disease-causing bacteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Presence of epileptiform patterns in EEGs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants Achieving PASI75 Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 30-day ED and Hospital readmission Rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Indexed end systolic volume decrease >15%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Anxiety of the caregivers
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Wechsler Memory Scale-III (WMS-III) Auditory Delayed Index
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Patient activation/coping
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Scores obtained with the different versions of the MOCA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: subjective concentration score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of participants with variceal rebleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Antigen loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: FAO value measured
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FAO Reliability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FAO sensitivity-specificity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volatile organic compounds in the exhaled breath condensate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in gut microbiome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Spine joint position reproduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Rotation Span Task Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Symmetry Span Task Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Operation Span Task Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: psychosocial burden of genital warts
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Overall Occurrence of Appropriate ICD Interventions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Patient-reported disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: postoperative level of anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Area under curve from dosing time to last measurement (AUC (0-t)) for MD1003
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under curve from dosing time to infinity (AUC(0-∞)) for MD1003
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum plasma drug concentration (Cmax) for MD1003
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of RRp Determination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in lung resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of children with HIV genome sequences
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of Significant Pain in PACU
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Agitation in PACU
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Post-Operative Nausea or Vomiting
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Expression of Cav1.4 calcium channels in Th17 lymphocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Breast cancer screening behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes